
|Videos|March 21, 2022
The role of doublet and triplet therapies in prostate cancer
Author(s)Urology Times staff
“There are many studies now that have shown that these doublets and triplets seem to be better than just ADT alone,” says William K. Oh, MD.
Advertisement
In this video, William K. Oh, MD, discusses the rise of doublet and triplet therapies in the treatment of prostate cancer, and what questions are still being investigated related to these novel treatments.Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5


















